News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,454 Results
Type
Article (43707)
Company Profile (473)
Press Release (694262)
Multimedia
Podcasts (123)
Webinars (20)
Section
Business (209336)
Career Advice (2039)
Deals (36154)
Drug Delivery (119)
Drug Development (83987)
Employer Resources (174)
FDA (16694)
Job Trends (15189)
News (354193)
Policy (33281)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2657)
Accelerated approval (36)
Adcomms (28)
Allergies (146)
Alliances (51114)
ALS (179)
Alzheimer's disease (1732)
Antibody-drug conjugate (ADC) (330)
Approvals (16932)
Artificial intelligence (548)
Autoimmune disease (161)
Automation (39)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (193)
Biotechnology (331)
Bladder cancer (162)
Brain cancer (60)
Breast cancer (654)
Cancer (4948)
Cardiovascular disease (418)
Career advice (1724)
Career pathing (38)
CAR-T (294)
CDC (46)
Celiac Disease (2)
Cell therapy (784)
Cervical cancer (36)
Clinical research (71469)
Collaboration (1804)
Company closure (4)
Compensation (1185)
Complete response letters (66)
COVID-19 (2772)
CRISPR (98)
C-suite (888)
Cystic fibrosis (152)
Data (6334)
Decentralized trials (2)
Denatured (39)
Depression (142)
Diabetes (505)
Diagnostics (6753)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (270)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (245)
Earnings (91477)
Editorial (61)
Employer branding (21)
Employer resources (153)
Events (121059)
Executive appointments (1008)
FDA (19855)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1537)
Gene editing (214)
Generative AI (45)
Gene therapy (649)
GLP-1 (1012)
Government (4761)
Grass and pollen (6)
Guidances (384)
Healthcare (19208)
HIV (60)
Huntington's disease (47)
IgA nephropathy (87)
Immunology and inflammation (275)
Immuno-oncology (62)
Indications (111)
Infectious disease (3048)
Inflammatory bowel disease (199)
Inflation Reduction Act (17)
Influenza (119)
Intellectual property (254)
Interviews (315)
IPO (16933)
IRA (53)
Job creations (3713)
Job search strategy (1440)
JPM (66)
Kidney cancer (16)
Labor market (86)
Layoffs (582)
Leadership (33)
Legal (8026)
Liver cancer (93)
Longevity (14)
Lung cancer (668)
Lymphoma (382)
Machine learning (43)
Management (59)
Manufacturing (813)
MASH (171)
Medical device (13924)
Medtech (13977)
Mergers & acquisitions (20301)
Metabolic disorders (1322)
Multiple sclerosis (165)
NASH (19)
Neurodegenerative disease (341)
Neuropsychiatric disorders (97)
Neuroscience (3027)
Neurotech (1)
NextGen: Class of 2026 (6770)
Non-profit (4585)
Now hiring (67)
Obesity (633)
Opinion (282)
Ovarian cancer (168)
Pain (205)
Pancreatic cancer (233)
Parkinson's disease (295)
Partnered (34)
Patents (500)
Patient recruitment (505)
Peanut (57)
People (60327)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22480)
Phase 2 (31509)
Phase 3 (23294)
Pipeline (5363)
Policy (298)
Postmarket research (2602)
Preclinical (9609)
Press Release (67)
Prostate cancer (246)
Psychedelics (56)
Radiopharmaceuticals (298)
Rare diseases (896)
Real estate (6064)
Recruiting (71)
Regulatory (25020)
Reports (53)
Research institute (2489)
Resumes & cover letters (354)
Rett syndrome (27)
RNA editing (21)
RSV (78)
Schizophrenia (156)
Series A (255)
Series B (202)
Service/supplier (11)
Sickle cell disease (104)
Special edition (27)
Spinal muscular atrophy (162)
Sponsored (43)
Startups (3805)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (85)
The Weekly (82)
Vaccines (1036)
Venture capital (95)
Weight loss (410)
Women's health (93)
Worklife (19)
Date
Today (29)
Last 7 days (572)
Last 30 days (2103)
Last 365 days (30692)
2026 (3581)
2025 (31065)
2024 (36308)
2023 (41029)
2022 (52280)
2021 (56765)
2020 (54930)
2019 (47419)
2018 (35697)
2017 (33029)
2016 (32354)
2015 (38413)
2014 (32189)
2013 (27115)
2012 (29226)
2011 (29863)
2010 (27993)
Location
Africa (755)
Alabama (89)
Alaska (7)
Arizona (318)
Arkansas (14)
Asia (40714)
Australia (6764)
California (11516)
Canada (3314)
China (1144)
Colorado (489)
Connecticut (497)
Delaware (339)
Europe (89263)
Florida (1700)
Georgia (360)
Hawaii (3)
Idaho (61)
Illinois (886)
India (66)
Indiana (527)
Iowa (24)
Japan (438)
Kansas (130)
Kentucky (40)
Louisiana (27)
Maine (72)
Maryland (1407)
Massachusetts (8370)
Michigan (327)
Minnesota (641)
Mississippi (5)
Missouri (130)
Montana (34)
Nebraska (28)
Nevada (122)
New Hampshire (83)
New Jersey (3065)
New Mexico (31)
New York (3019)
North Carolina (1535)
North Dakota (9)
Northern California (5604)
Ohio (338)
Oklahoma (21)
Oregon (45)
Pennsylvania (2307)
Puerto Rico (24)
Rhode Island (49)
South America (1122)
South Carolina (66)
South Dakota (1)
Southern California (4466)
Tennessee (175)
Texas (1771)
United States (40964)
Utah (341)
Vermont (1)
Virginia (268)
Washington D.C. (82)
Washington State (956)
West Virginia (4)
Wisconsin (115)
Wyoming (2)
738,454 Results for "effector therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Opinion
To Broaden Access to CAR Ts, Mitigate Their Side Effects
The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome limits the reach of these transformative cancer therapies.
January 12, 2026
·
4 min read
·
Teresa Whalen
Business
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company’s development programs.
June 24, 2024
·
2 min read
Biotech Bay
eFFECTOR Therapeutics to Participate in Upcoming April 2024 Investor Conference
eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced that the Company will present at the Stifel Virtual Oncology Forum on Tuesday, April 16th at 11:30 am ET.
April 9, 2024
·
1 min read
Business
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
May 9, 2024
·
12 min read
Press Releases
Excellergy Debuts with $70 Million Series A Financing to Advance First-in-Class Portfolio of Trifunctional Effector Cell Response Inhibitors (ECRIs) for Complete Allergic Control
October 14, 2025
·
4 min read
Biotech Bay
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that Steve Worland, Ph.D., president, and chief executive officer of eFFECTOR, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th at 10:40 am ET.
February 5, 2024
·
2 min read
Business
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer
eFFECTOR Therapeutics, Inc. today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive (ER+) endometrial cancer.
May 20, 2024
·
6 min read
Business
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
March 25, 2024
·
15 min read
Biotech Bay
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that it will host a virtual investor R&D Day on Wednesday, January 24, 2024, at 4:30 pm ET.
January 9, 2024
·
5 min read
Drug Development
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
eFFECTOR Therapeutics, Inc. today announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer (NSCLC) with PD-L1 ≥50%.
April 4, 2024
·
6 min read
1 of 73,846
Next
